/
ALC
$66.97-$0.64 (-0.95%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$33.1B
488M shares
52-week range
$61.84 – $92.55
17% from low
Exchange
NYSE
CS
Borrow rate
0.71%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-3.40
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.15B | $7.51B | $6.83B | $8.29B | $8.72B | $9.46B | $9.91B | $10.40B |
| Cost of revenue | $3.96B | $3.85B | $3.89B | $3.64B | $3.97B | $4.21B | $4.40B | $4.66B |
| Gross profit | $3.19B | $3.66B | $2.94B | $4.65B | $4.75B | $5.25B | $5.51B | $5.75B |
| Gross margin | 44.6% | 48.8% | 43.0% | 56.1% | 54.5% | 55.5% | 55.6% | 55.2% |
| R&D | $587.0M | $656.0M | $673.0M | $842.0M | $702.0M | $859.0M | $876.0M | $990.0M |
| Operating income | −$248.0M | −$187.0M | −$482.0M | $580.0M | $672.0M | $1.04B | $1.41B | $1.36B |
| EBITDA | $1.35B | $1.26B | $1.18B | $1.76B | $1.78B | $2.24B | $2.68B | $2.35B |
| Net income | −$227.0M | −$656.0M | −$531.0M | $376.0M | $335.0M | $974.0M | $1.02B | $980.0M |
| Net margin | -3.2% | -8.7% | -7.8% | 4.5% | 3.8% | 10.3% | 10.3% | 9.4% |
| EPS (diluted) | -0.46 | -1.34 | -1.09 | 0.76 | 0.68 | 1.96 | 2.05 | 1.98 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10.7B | $3.35 | $3.26–$3.72 | 17 |
| 2027 | $11.4B | $3.84 | $3.73–$3.96 | 17 |
| 2028 | $12.1B | $4.35 | $2.87–$5.38 | 15 |
| 2029 | $12.7B | $5.00 | $4.94–$5.10 | 10 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$80.61
Price
$66.97
Implied upside
+20%
Peer comparison
Alcon Inc. Ordinary Shares
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
www.alcon.com- Employees
- 25,942
- IPO / List date
- Apr 9, 2019
Held by traders on TradeandTell
No one on the platform currently holds ALC.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ALC as of their last filing.
Insider activity (SEC Form 4)
Dividend history
TTM yield · 1.19% ($0.80/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-06 | $0.2800 | 2026-05-07 |
| 2025-05-14 | $0.2800 | 2025-05-15 |
| 2024-05-14 | $0.2400 | 2024-05-16 |
Recent trades on TradeandTell
No one on the platform has traded ALC yet.
